Skip to content
drillr.ai
Sign up

EVMN

Evommune, Inc.

NYSE · Healthcare · Biotechnology · US

$12.27
+2.25%
Ask drillr

  • Jun 30, 2026, 16:16 UTC

    Evommune's phase IIb clinical trial for EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint.

    Source: